Delivery Order SPE2DB22D1106-SPE2DB23FEHB7
- Not listed
- This is a federal contract award from the Defense Logistics Agency (DLA) Troop Support Medical to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $7,775.07, is for the delivery of NARCAN 4 MG NASAL SPRAY 2S, a critical medication used to reverse opioid overdoses. This award is a delivery order under a larger Indefinite Delivery Contract (IDC) held by AmerisourceBergen with the DLA, valued at $999,999,999 and running...
- This federal contract award, valued at $5,486.40, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract provides for the delivery of NARCAN 4 MG NASAL SPRAY 2S, a critical medication used for the treatment of opioid overdose. The contract is structured as a Delivery Order under an Indefinite Delivery Contract (IDC) held by Amerisourcebergen's parent company, Cencora, Inc., with the DLA...
- This federal contract award, valued at $4,337.14, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of NARCAN 4 MG NASAL SPRAY 2S, a critical medication used for opioid overdose reversal. The contract is a Delivery Order under a larger Indefinite Delivery Contract (IDC) that Amerisourcebergen holds with the DLA Troop Support Medical, valued at $999,999,999 and...
- This federal contract award, valued at $1,561.44, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The contract is for the delivery of NARCAN 4 MG NASAL SPRAY 2S, a critical medication used to treat opioid overdoses. The award is a Delivery Order under a larger Indefinite Delivery Contract (IDC) held by AmerisourceBergen's parent company, Cencora, Inc., with the DLA Troop Support Medical. This IDC, valued at up to...
- This federal contract award is for the delivery of NARCAN 4 MG NASAL SPRAY 2S, a critical opioid overdose reversal medication. The contract, valued at $5,887.54, was awarded to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, by the Defense Logistics Agency (DLA). The contract is a Delivery Order under a larger Indefinite Delivery Contract (IDC) valued at $999,999,999 that Amerisourcebergen holds with the DLA Troop Support Medical. This IDC serves as a primary vehicle for...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $4,140.17, is for the delivery of NARCAN 4 MG NASAL SPRAY 2S, a critical medication used for opioid overdose reversal. The award is a delivery order under a larger Indefinite Delivery Contract (IDC) held by Amerisourcebergen's parent company, Cencora, Inc., with the DLA Troop Support Medical....
- This is a federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $5,315.50, is for the procurement of NARCAN 4 MG NASAL SPRAY 2S, a critical opioid overdose reversal medication. The contract is a Delivery Order under a larger Indefinite Delivery Contract (IDC) held by AmerisourceBergen with the DLA Troop Support Medical, valued at $999,999,999 and running...
- This federal contract award, valued at $1,601.23, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of NARCAN 4 MG NASAL SPRAY 2S, a critical medication used for opioid overdose reversal. The contract has an ultimate completion date of July 19, 2024 and is structured as a Firm Fixed Price Delivery Order. The award is not associated with a set-aside designation,...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,328.22 delivery order is for the supply of NARCAN 4 MG NASAL SPRAY 2S, a critical opioid overdose treatment medication. The award is part of a larger Indefinite Delivery Contract (IDC) valued at up to $999,999,999 that Amerisourcebergen's parent company, Cencora, Inc., holds with the DLA Troop Support Medical....
- This federal contract award, valued at $2,890.68, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is a Delivery Order for the procurement of 4,562,866,740 units of NARCAN 4 MG NASAL SPRAY 2S, a critical medication used for the treatment of opioid overdose. The contract has an ultimate completion date of November 21, 2023 and utilizes a Firm Fixed Price pricing type....
- SPE2DB22D1106Indefinite Delivery Contract
- SPE2DB22D1106-SPE2DB23FEHB7Delivery Order
This federal contract award, valued at $17,982.89, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of NARCAN 4 MG NASAL SPRAY 2S, a critical medication used for opioid overdose reversal. The contract is a Delivery Order under an Indefinite Delivery Contract (IDC) valued at $999,999,999 that AmerisourceBergen holds with the DLA Troop Support Medical. This IDC serves as a primary vehicle for providing a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. The contract encompasses critical medical commodities including specialty medications, brand-name and generic drugs, vaccines, syringes, vials, and test kits across multiple therapeutic domains. The current award does not have a set-aside designation, indicating open competition.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $18.0k | 5/9/23 |